Results 1 to 10 of about 528 (93)

Modular access to alkylgermanes via reductive germylative alkylation of activated olefins under nickel catalysis [PDF]

Nature Communications, 2023
Carbon-introducing difunctionalization of C-C double bonds enabled by transition-metal catalysis is one of most straightforward and efficient strategies to construct C-C and C-X bonds concurrently from readily available feedstocks towards structurally ...
Rui Gu, Xiujuan Feng, Ming Bao, Xuan Zhang   +3 more
doaj   +2 more sources

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study [PDF]

Therapeutic Advances in Drug Safety, 2022
Introduction: The primary aim of this study was to compare the incidence of venous thromboembolism (VTE) among women initiating ospemifene vs other selective estrogen receptor modulator (SERM) therapies for estrogen-deficiency conditions or breast cancer
Beth L. Nordstrom, Bin Cai, Fabio De Gregorio, Lu Ban, Kathy H. Fraeman, Yuki Yoshida, Trevor Gibbs   +6 more
doaj   +2 more sources

Long-term effects of ospemifene on densitometric and bone metabolism biomarkers in postmenopausal women reporting Vulvar and Vaginal Atrophy (VVA) [PDF]

BMC Women's Health
Ospemifene (OSP), a Selective Estrogen Receptor Modulator (SERM), is recommended for treating vulvovaginal atrophy (VVA) in postmenopausal women (PMW). Previous 12 mm data suggested that OSP therapy had beneficial effects on bone mineral and biochemical ...
Silvia Maffei, Alessia Formica, Dario Corsini, Michela Franchini   +3 more
doaj   +2 more sources

Case-Based Perspectives on the Management of Genitourinary Syndrome of Menopause [PDF]

Clinics and Practice
Background and Objectives: Genitourinary syndrome of menopause (GSM), previously known as vulvovaginal atrophy, is a chronic, progressive hypoestrogenic condition affecting vulvovaginal, urinary and sexual health in women. Common symptoms include vaginal
Jissy Cyriac, Richa Sood
doaj   +2 more sources

Update on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach [PDF]

Life
This scoping review explores the therapeutic strategies available for managing genitourinary syndrome of menopause (GSM), a condition often underdiagnosed and undertreated despite significantly affecting women’s quality of life.
Ilaria Cuccu, Tullio Golia D’Augè, Ilaria Firulli, Emanuele De Angelis, Giovanni Buzzaccarini, Ottavia D’Oria, Aris Raad Besharat, Donatella Caserta, Giorgio Bogani, Ludovico Muzii, Violante Di Donato, Andrea Giannini   +11 more
doaj   +2 more sources

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

International Journal of Women's Health, 2013
Lin H Soe, Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, University of California, Davis, Sacramento, CA, USA Abstract: Ospemifene is a selective estrogen ...
Gregory T Würz, Michael W Degregorio
exaly   +2 more sources

Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

International Journal of Women's Health
Giulia Marchetti,1 Annika Taithongchai,2 Dudley Robinson2 1Urogynaecology Department, Irmandade de Misericórdia da Santa Casa de São Paulo, Sao Paulo, Brazil; 2Urogynaecology Department, King’s College Hospital, London, UKCorrespondence: Dudley Robinson,
Giulia Marchetti, Dudley Robinson
exaly   +2 more sources

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies

Drugs in Context, 2020
Vaginal laser therapy is a non-hormonal treatment option for vulvovaginal atrophy (VVA), a component of the genitourinary syndrome of menopause. Through a microablative and/ or thermal effect on atrophic vaginal epithelium, laser therapy activates growth
Félix Lugo Salcedo, Zuramis Estrada Blanco   +1 more
doaj   +1 more source

Vulvovaginal atrophy in the CRETA study: the healthcare professionals’ perception

Gynecological Endocrinology, 2023
Objectives The objective is to assess the perception of gynecologists regarding patients’ adherence to vulvovaginal atrophy (VVA) treatments, to evaluate the gynecologists’ opinions on what their patients think about treatment adherence, and to compare ...
María J. Cancelo, Rafael Sánchez Borrego, Santiago Palacios, Laura Baquedano, Tanit Corbacho Garza, Noelia Fernández Aller, Carmen García Ferreiro, Juan José Quijano Martín, A. Javier González Calvo   +8 more
doaj   +1 more source

Ospemifene for vulvar and vaginal atrophy: an overview

Drugs in Context, 2020
The menopause-related decline in estrogen levels leads to an array of genital, sexual, and urinary symptoms collectively known as genitourinary syndrome of menopause. The constellation of symptoms associated with vulvar and vaginal atrophy (VVA) can have
Santiago Palacios
doaj   +1 more source